Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021


HomeLevita® MagneticsLevita Magnetics Announces FDA Clearance of Expanded Indication for Magnetic Surgical System for Use in Bariatric Procedures

Levita Magnetics Announces FDA Clearance of Expanded Indication for Magnetic Surgical System for Use in Bariatric Procedures

Technology Minimizes Invasiveness of Laparoscopic Procedures Promising Fewer Incisions and Scarring, While Facilitating Surgeon Access and Visualization

October 22, 2018

Levita Magnetics, a company dedicated to improving the outcomes of surgical procedures through Magnetic Surgery®, today announced that the U.S. Food and Drug Administration (FDA) has granted the company an expanded indication to market the company’s first-of-its-kind Levita® Magnetic Surgical System for use in bariatric procedures. Initially indicated for use in gallbladder removal procedures, the shaftless Magnetic Surgical System reduces the number of incisions necessary for the indicated procedures.

Levita Magnetics highlights the Levita System is designed to facilitate access and visualization of the surgical site while minimizing invasiveness. In conventional laparoscopic procedures, shafted surgical instruments are introduced by fixed-position trocars inserted through incisions in the abdomen. The use of trocars is associated with risks relating to major bowel and vessel injury, incisional pain, bleeding, scarring, hernias, and infection. In addition, shafted instruments can impair surgeon visualization by cluttering the operative field, cause instrument collisions, and restrict movement as a result of their fixed pivot point. The shaftless Levita System reduces the number of incisions and trocars necessary, while also providing surgeons the ability to move instruments without the constraints of a fixed-position pivot point.

“Magnetic Surgery with the Levita System will allow us to offer a less invasive alternative to our bariatric patients. Bariatric surgery patients are interested in new options that minimize incisions and result in better cosmetic outcomes, and the Levita System has been effective in delivering these results in our preliminary experience to date,” said Dana Portenier, M.D., Chief of the Metabolic and Weight Loss Surgery division at Duke University Health System in Durham, North Carolina. “I have used the Levita System since its initial FDA clearance, and believe it is an important new option for patients electing to undergo bariatric surgery.”

According to the Centers for Disease Control and Prevention (CDC), nearly 40 percent of U.S. adults (93 million Americans) have a body mass index classifying them as obese.1 Long-term evidence from studies of bariatric surgery outcomes has demonstrated a significant benefit for weight loss as well as diabetes recovery, a lower risk of cardiovascular disease, and other metabolic and musculoskeletal benefits.2 There has been a 44 percent increase in bariatric procedures in the United States since 2011.3

“This new indication is another exciting milestone for Levita and a significant step toward fulfilling our vision to enhance patient outcomes by minimizing the footprint of surgical procedures across multiple indications and broad patient populations,” said surgeon Alberto Rodriguez-Navarro, CEO and founder, Levita Magnetics. “We are pleased that our technology allows surgeons to offer a less-invasive alternative to patients considering bariatric procedures.”

To date, patients have undergone Magnetic Surgery at leading clinical centers including the Cleveland Clinic, UT Southwestern Medical Center, Stanford University and Duke University, among others.

The Levita Magnetic Surgical System enables reduced-port laparoscopic surgical procedures designed to minimize the footprint of surgery. The system, which consists of an external magnet placed on the skin that controls a shaftless detachable grasper, enables instruments to move without the constraints of a fixed-position pivot point, and facilitates access and visualization of the surgical site.

In the United States, the Levita Magnetic Surgical System is indicated to grasp and retract the body and the fundus of the gall bladder in laparoscopic cholecystectomy procedures and the liver in bariatric procedures to facilitate access and visualization of the surgical site in patients with a BMI range of 20-60 kg/m2.



2 Panagiotou OA, Markozannes G, Adam GP, et al. Comparative Effectiveness and Safety of Bariatric Procedures in Medicare-Eligible PatientsA Systematic Review. JAMA Surg. Published online September 05, 2018. doi:10.1001/jamasurg.2018.3326


Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy